Israel's IceCure Medical 2025 gross margin falls to 36% on higher costs

Reuters03-17
Israel's IceCure Medical 2025 gross margin falls to 36% on higher costs

Overview

  • Israel cryoablation device maker's 2025 revenue rose, driven by global sales growth

  • Gross margin for 2025 declined to 36% from 44% yr/yr, due to higher costs

  • Net loss for 2025 narrowed

Outlook

  • Company expects to on-board 30 hybrid commercial-clinical sites in U.S. for post-marketing study in 2026

  • IceCure expects expanded reimbursement coverage for low-risk breast cancer procedures in U.S.

Result Drivers

  • PROSENSE ADOPTION - Record sales driven by increased global and U.S. adoption of ProSense following FDA clearance and new medical society guidelines

  • REGIONAL SALES MIX - Sales growth in Europe, Latin America, North America, and China offset by lower sales in Japan

  • HIGHER COSTS - Gross margin declined due to increased costs for raw materials, subcontractors, auxiliary materials, and payroll

Company press release: ID:nPn4znbfla

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

FY Adjusted Gross Margin

36.00%

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for Icecure Medical Ltd is $3.13, about 328.1% above its March 16 closing price of $0.73

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment